NASDAQ:PYXS

Pyxis Oncology (PYXS) Stock Price, News & Analysis

Pyxis Oncology logo
$1.80 +0.13 (+7.44%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$1.81 +0.01 (+0.28%)
As of 11/20/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Pyxis Oncology Stock (NASDAQ:PYXS)

Advanced

Key Stats

Today's Range
$1.70
▼
$1.99
50-Day Range
$1.41
▼
$3.43
52-Week Range
$1.03
▼
$5.55
Volume
3.05 million shs
Average Volume
855,124 shs
Market Capitalization
$215.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.71
Consensus Rating
Moderate Buy

Company Overview

Pyxis Oncology, Inc. is a clinical-stage biotechnology company developing antibody-based medicines for people with difficult-to-treat cancers. Its research focuses on targeted therapies intended to attack tumors while limiting effects on healthy tissue.

The company’s pipeline includes PYX-201, an investigational antibody-drug conjugate designed to target EDB+ fibronectin, a protein found in the tumor microenvironment. The program reflects Pyxis Oncology’s broader approach of using antibodies to direct cancer-fighting agents to tumor-associated targets.

Founded in 2019 and based in Boston, Massachusetts, Pyxis Oncology was co-founded by Lara Sullivan, who has served as its president and chief executive officer. The company is focused on developing its therapies and does not have marketed products.

AI Generated. May Contain Errors.

Pyxis Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

PYXS MarketRank™: 
2.704217458315 of 5 stars

Pyxis Oncology scored higher than 54% of companies evaluated by MarketBeat, and ranked 424th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pyxis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Pyxis Oncology has a consensus price target of $8.71, representing about 382.8% upside from its current price of $1.81.

  • Amount of Analyst Coverage

    Pyxis Oncology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Pyxis Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for Pyxis Oncology are expected to grow in the coming year, from ($1.12) to ($0.80) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pyxis Oncology is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pyxis Oncology is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pyxis Oncology has a P/B Ratio of 5.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.06% of the float of Pyxis Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Pyxis Oncology has a short interest ratio ("days to cover") of 5.82.
  • Change versus previous month

    Short interest in Pyxis Oncology has recently increased by 4.12%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Pyxis Oncology does not currently pay a dividend.

  • Dividend Growth

    Pyxis Oncology does not have a long track record of dividend growth.

  • News Sentiment

    Pyxis Oncology has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Pyxis Oncology this week, compared to 3 articles on an average week.
  • Search Interest

    2 people have searched for PYXS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Pyxis Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pyxis Oncology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.50% of the stock of Pyxis Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    39.07% of the stock of Pyxis Oncology is held by institutions.

  • Read more about Pyxis Oncology's insider trading history.
Receive PYXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PYXS Stock News Headlines

William Blair Upgrades Pyxis Oncology (NASDAQ:PYXS) to "Outperform"
HC Wainwright Reaffirms Buy Rating for Pyxis Oncology (NASDAQ:PYXS)
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Headlines

PYXS Stock Analysis - Frequently Asked Questions

Pyxis Oncology's stock was trading at $1.15 at the start of the year. Since then, PYXS stock has increased by 57.0% and is now trading at $1.8050.

Pyxis Oncology, Inc. (NASDAQ:PYXS) issued its quarterly earnings results on Thursday, November, 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.03.

Pyxis Oncology (PYXS) raised $158 million in an initial public offering (IPO) on Wednesday, October 6th 2021. The company issued 10,500,000 shares at $14.00-$16.00 per share.

Top institutional shareholders of Pyxis Oncology include Blue Owl Capital Holdings LP (1.20%), Marshall Wace LLP (0.64%), State Street Corp (0.39%) and Goldman Sachs Group Inc. (0.12%). Insiders that own company stock include Pamela Ann Connealy and Rachel Humphrey.
View institutional ownership trends
.

Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pyxis Oncology investors own include NVIDIA (NVDA), Iovance Biotherapeutics (IOVA), Palantir Technologies (PLTR), Viking Therapeutics (VKTX), Voyager Therapeutics (VYGR), Rocket Pharmaceuticals (RCKT) and Nkarta (NKTX).

Company Calendar

Last Earnings
11/05/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PYXS
CIK
1782223
Fax
N/A
Employees
56
Year Founded
2019

Price Target and Rating

High Price Target
$19.00
Low Price Target
$5.00
Potential Upside/Downside
+382.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$79.62 million
Net Margins
N/A
Pretax Margin
-775.55%
Return on Equity
-252.36%
Return on Assets
-120.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.96
Quick Ratio
2.96

Sales & Book Value

Annual Sales
$11.04 million
Price / Sales
19.56
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.35 per share
Price / Book
5.16

Miscellaneous

Outstanding Shares
119,608,000
Free Float
107,049,000
Market Cap
$215.89 million
Optionable
Optionable
Beta
1.41

Social Links

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:PYXS) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners